Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Prof Wynand Goosen
Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards.

Being nominated for a ‘Science Oscar’ is exciting and validates nominees’ efforts, particularly in a field as challenging and essential as infectious diseases, for which they are recognised at the highest level. 

This is according to Prof Wynand Goosen, Professor and Lead for One Health in the Department of Microbiology and Biochemistry at the University of the Free State (UFS). He was nominated in the TW Kambule-NSTF Award: Researcher category of the 2024/25 NSTF-South32 Awards for his landmark discovery of Mycobacterium bovis infection in humans in South Africa – the first confirmed cases in the country. 

Prof Goosen, who previously won the NSTF-South32 Emerging Researcher Award, says the nomination is a powerful affirmation of the impact that focused, interdisciplinary research can have. It reflects not only his personal commitment but also the dedication of a talented and hard-working team. “I am honoured and humbled to be nominated. It is also a testament to the support and vision of UFS, particularly as we position ourselves as leaders in One Health research in South Africa,” he says. 

 

Focus of research 

He was nominated by Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation, and Prof Paul Oberholster, Dean for the Faculty of Natural and Agricultural Sciences (NAS) at the UFS, and Prof Nico Gey van Pittius and Prof Elmi Muller from Stellenbosch University (US). The NSTF Awards, known as the ‘Science Oscars’of SA, honour, reward, celebrate, profile and promote outstanding contributions to science, engineering and technology (SET) and innovation in South Africa.

“The nomination,” Prof Goosen continues, “recognises our work in the field of zoonotic tuberculosis (TB) and other emerging infectious diseases at the human-animal-environment interface. Our research focuses on the molecular detection and characterisation of pathogenic mycobacteria in wildlife, livestock, and human populations, with the aim of informing better surveillance, diagnostics, and control strategies — particularly in high-risk ecosystems. This includes novel applications in wildlife TB surveillance and understanding the transmission dynamics between animals and people.”

 

Establishing a Kovsie One Health Research Unit

This research is critically important as South Africa continues to face a high burden of tuberculosis, including zoonotic TB, which often goes under-detected in rural and wildlife-rich areas. Understanding how these pathogens circulate between humans, animals, and the environment, explains Prof Goosen, is essential for effective disease control and to mitigate future pandemics. This work directly supports national health priorities, informs policy, and contributes to global strategies for One Health.

Prof Goosen and the team are in the process of laying the groundwork for the establishment of a Kovsie One Health Research Unit, which will serve as a collaborative platform for research spanning human, animal, and environmental health. One of their key projects involves expanding TB and AMR surveillance in wildlife-livestock-human interfaces, using cutting-edge diagnostics and genomic tools. They are also initiating partnerships with industry and international institutions to address emerging zoonoses and environmental pathogens in a transdisciplinary manner.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept